Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
I’d be curious if there might also be a cultural aspect at play.
Apparently in America, their portions tend to be quite large, since the expectation is to get as much for your money as possible. Anything you can’t stomach can then be taken home to finish another day.
Whereas many other places don’t tend to do that. Food served in the restaurant is to be eaten there, and wanting a take-away container to take your meal home means paying extra for the container.